Adult-onset Still's disease secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Overview
Secondary prevention of adult-onset Still’s disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.
Secondary Prevention
Secondary Prevention
Secondary prevention of adult-onset Still’s disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.[1]
References
References
- ↑ Nishina N, Kaneko Y, Kameda H, Takeuchi T (May 2015). “The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: A retrospective, single-center study”. Mod Rheumatol. 25 (3): 401–4. doi:10.3109/14397595.2014.973659. PMID 25401229.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH